352 related articles for article (PubMed ID: 28228316)
1. Gonadotropin-releasing hormone analogue as sole luteal support in antagonist-based assisted reproductive technology cycles.
Bar Hava I; Blueshtein M; Ganer Herman H; Omer Y; Ben David G
Fertil Steril; 2017 Jan; 107(1):130-135.e1. PubMed ID: 28228316
[TBL] [Abstract][Full Text] [Related]
2. Is the effect of premature elevated progesterone augmented by human chorionic gonadotropin versus gonadotropin-releasing hormone agonist trigger?
Connell MT; Patounakis G; Healy MW; DeCherney AH; Devine K; Widra E; Levy MJ; Hill MJ
Fertil Steril; 2016 Sep; 106(3):584-589.e1. PubMed ID: 27178228
[TBL] [Abstract][Full Text] [Related]
3. Luteal phase support in in vitro fertilization.
Yanushpolsky EH
Semin Reprod Med; 2015 Mar; 33(2):118-27. PubMed ID: 25734349
[TBL] [Abstract][Full Text] [Related]
4. Effect of the initiation of progesterone supplementation in in vitro fertilization-embryo transfer outcomes: a prospective randomized controlled trial.
Gao J; Gu F; Miao BY; Chen MH; Zhou CQ; Xu YW
Fertil Steril; 2018 Jan; 109(1):97-103. PubMed ID: 29175065
[TBL] [Abstract][Full Text] [Related]
5. Impact of luteal phase support with vaginal progesterone on the clinical pregnancy rate in intrauterine insemination cycles stimulated with gonadotropins: a randomized multicenter study.
Peeraer K; D'Hooghe T; Laurent P; Pelckmans S; Delvigne A; Laenen A; Welkenhuysen M; Wyns C; De Neubourg D
Fertil Steril; 2016 Nov; 106(6):1490-1495. PubMed ID: 27565253
[TBL] [Abstract][Full Text] [Related]
6. Comparison of live-birth defects after luteal-phase ovarian stimulation vs. conventional ovarian stimulation for in vitro fertilization and vitrified embryo transfer cycles.
Chen H; Wang Y; Lyu Q; Ai A; Fu Y; Tian H; Cai R; Hong Q; Chen Q; Shoham Z; Kuang Y
Fertil Steril; 2015 May; 103(5):1194-1201.e2. PubMed ID: 25813280
[TBL] [Abstract][Full Text] [Related]
7. Dual trigger with combination of gonadotropin-releasing hormone agonist and human chorionic gonadotropin significantly improves the live-birth rate for normal responders in GnRH-antagonist cycles.
Lin MH; Wu FS; Lee RK; Li SH; Lin SY; Hwu YM
Fertil Steril; 2013 Nov; 100(5):1296-302. PubMed ID: 23993928
[TBL] [Abstract][Full Text] [Related]
8. The effect of luteal phase vaginal estradiol supplementation on the success of in vitro fertilization treatment: a prospective randomized study.
Engmann L; DiLuigi A; Schmidt D; Benadiva C; Maier D; Nulsen J
Fertil Steril; 2008 Mar; 89(3):554-61. PubMed ID: 17678651
[TBL] [Abstract][Full Text] [Related]
9. Assessing the adequacy of gonadotropin-releasing hormone agonist leuprolide to trigger oocyte maturation and management of inadequate response.
Chang FE; Beall SA; Cox JM; Richter KS; DeCherney AH; Levy MJ
Fertil Steril; 2016 Oct; 106(5):1093-1100.e3. PubMed ID: 27341988
[TBL] [Abstract][Full Text] [Related]
10. The impact of luteal serum progesterone levels on live birth rates-a prospective study of 602 IVF/ICSI cycles.
Thomsen LH; Kesmodel US; Erb K; Bungum L; Pedersen D; Hauge B; Elbæk HO; Povlsen BB; Andersen CY; Humaidan P
Hum Reprod; 2018 Aug; 33(8):1506-1516. PubMed ID: 29955789
[TBL] [Abstract][Full Text] [Related]
11. Is the type of gonadotropin-releasing hormone suppression protocol for ovarian hyperstimulation associated with ectopic pregnancy in fresh autologous cycles for in vitro fertilization?
Londra L; Moreau C; Strobino D; Bhasin A; Zhao Y
Fertil Steril; 2016 Sep; 106(3):666-72. PubMed ID: 27320035
[TBL] [Abstract][Full Text] [Related]
12. Vaginal (Crinone 8%) gel vs. intramuscular progesterone in oil for luteal phase support in in vitro fertilization: a large prospective trial.
Silverberg KM; Vaughn TC; Hansard LJ; Burger NZ; Minter T
Fertil Steril; 2012 Feb; 97(2):344-8. PubMed ID: 22188983
[TBL] [Abstract][Full Text] [Related]
13. Intranasal gonadotropin-releasing hormone agonist (GnRHa) for luteal-phase support following GnRHa triggering, a novel approach to avoid ovarian hyperstimulation syndrome in high responders.
Bar-Hava I; Mizrachi Y; Karfunkel-Doron D; Omer Y; Sheena L; Carmon N; Ben-David G
Fertil Steril; 2016 Aug; 106(2):330-3. PubMed ID: 27114332
[TBL] [Abstract][Full Text] [Related]
14. Increased odds of live birth in fresh in vitro fertilization cycles with shorter ovarian stimulation.
Pereira N; Friedman C; Hutchinson AP; Lekovich JP; Elias RT; Rosenwaks Z
Fertil Steril; 2017 Jan; 107(1):104-109.e2. PubMed ID: 27793370
[TBL] [Abstract][Full Text] [Related]
15. Dual trigger for final oocyte maturation improves the oocyte retrieval rate of suboptimal responders to gonadotropin-releasing hormone agonist.
Lu X; Hong Q; Sun L; Chen Q; Fu Y; Ai A; Lyu Q; Kuang Y
Fertil Steril; 2016 Nov; 106(6):1356-1362. PubMed ID: 27490046
[TBL] [Abstract][Full Text] [Related]
16. Comparison of pregnancy rates in antagonist cycles after luteal support with GnRH-agonist versus progesterone: prospective randomized study.
Buhbut E; Nabulsi R; Avigdor G; Ben-Ami I
Arch Gynecol Obstet; 2023 Jul; 308(1):255-263. PubMed ID: 37186265
[TBL] [Abstract][Full Text] [Related]
17. Vitrified blastocyst transfer cycles with the use of only vaginal progesterone replacement with Endometrin have inferior ongoing pregnancy rates: results from the planned interim analysis of a three-arm randomized controlled noninferiority trial.
Devine K; Richter KS; Widra EA; McKeeby JL
Fertil Steril; 2018 Feb; 109(2):266-275. PubMed ID: 29338855
[TBL] [Abstract][Full Text] [Related]
18. Daily low-dose hCG stimulation during the luteal phase combined with GnRHa triggered IVF cycles without exogenous progesterone: a proof of concept trial.
Andersen CY; Elbaek HO; Alsbjerg B; Laursen RJ; Povlsen BB; Thomsen L; Humaidan P
Hum Reprod; 2015 Oct; 30(10):2387-95. PubMed ID: 26209535
[TBL] [Abstract][Full Text] [Related]
19. Multiple-dose versus single-dose gonadotropin-releasing hormone agonist after first in vitro fertilization failure associated with luteal phase deficiency: A randomized controlled trial.
Qu D; Li Y
J Int Med Res; 2020 Jun; 48(6):300060520926026. PubMed ID: 32495663
[TBL] [Abstract][Full Text] [Related]
20. Dual trigger with gonadotropin-releasing hormone agonist and standard dose human chorionic gonadotropin to improve oocyte maturity rates.
Griffin D; Feinn R; Engmann L; Nulsen J; Budinetz T; Benadiva C
Fertil Steril; 2014 Aug; 102(2):405-9. PubMed ID: 24842671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
